Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ladostigil in Mild Cognitive Impairment
NCT01429623Phase 2Completed
- Sponsor
- Avraham Pharmaceuticals Ltd.
- Start
- Feb 2012
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of ladostigil in Mild Cognitive Impairment (MCI), sponsored by Avraham Pharmaceuticals Ltd.. Started Feb 2012; status: completed.
02
Drugs
ladostigil
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT01429623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01429623.